SCHEMBL3554086

SCHEMBL3554086

CC(C)(C)C(=O)Nc1ccccc1OCCOc1ccc(C(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.56
LMNA P02545 3/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.49
MAPT P10636 2/20 0.49
TDP1 Q9NUW8 1/20 0.48
RAB9A P51151 1/20 0.48
CACNA1H O95180 1/20 0.47
CACNA1B Q00975 1/20 0.47
POLB P06746 1/20 0.47
CASP6 P55212 1/20 0.47
TSHR P16473 3/20 0.46
USP2 O75604 2/20 0.46
MAPK1 P28482 2/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3557828 0.85 PKM (0.54) PKMLMNASMN1; SMN2L3MBTL1MAPT
SCHEMBL3556306 0.84 RAB9A (0.56) PKMLMNASMN1; SMN2L3MBTL1RAB9A
SCHEMBL3559976 0.83 PKM (0.60) PKMLMNASMN1; SMN2L3MBTL1MAPT
SCHEMBL3555523 0.81 TSHR (0.56) PKMLMNASMN1; SMN2L3MBTL1MAPT
SCHEMBL3557989 0.81 F10 (0.62) PKMLMNASMN1; SMN2L3MBTL1MAPT
SCHEMBL3557542 0.81 GAA (0.56) PKMLMNASMN1; SMN2L3MBTL1RAB9A
SCHEMBL3555876 0.81 CACNA1H (0.57) PKMLMNASMN1; SMN2MAPTRAB9A
SCHEMBL3556661 0.81 L3MBTL1 (0.65) PKMLMNASMN1; SMN2L3MBTL1MAPT
SCHEMBL3556618 0.81 POLB (0.62) PKMLMNASMN1; SMN2L3MBTL1MAPT
SCHEMBL3560476 0.81 KMT2A (0.70) PKMLMNASMN1; SMN2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 PKM 990/4885LMNA 2120/4885SMN1; SMN2 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.